FLOWER MOUND, Texas, Nov. 19 /PRNewswire-FirstCall/ -- American HealthChoice, Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, a medical services company with medical clinics in Texas and Tennessee, is pleased to announce the first sales of the U.S. FDA approved OmniBody Scan, an infrared thermal imaging camera that detects patterns of abnormality within the human body and identifies problems early enough for prevention and treatment.
"Physicians purchasing these first systems have been trained and more systems will be sold soon," said Dr. Joseph W. Stucki, CEO. "We are also pleased to announce that our new and updated web site, explaining the product and its myriad uses, has been activated at: http://www.omnibodyscan.com
"AMHI also has signed a distribution agreement covering the State of Texas for the purchase of a minimum of 15 cameras annually," Dr. Stucki said. "We have spoken to a number of oncologists who are very excited about the medical infrared technology we are bringing to the health care sector. I am confident that we will be successful in negotiating exclusive distribution agreements in other states, Canada, Mexico and elsewhere."
The OmniBody Scan is a non-invasive tool with no harmful side effects. It is manufactured exclusively for American HealthChoice by a respected infrared imaging manufacturer with years of successful experience in this field. "Our product adheres to the highest standards of thermography. It is easy to use and offers a very high grade of technology and quality. With its infrared technology, it allows an oncologist to find cancers, including breast cancer, years away from becoming a mass large enough to be detected by mammography, CT scans, MRIs or Ultrasound," Dr. Stucki said.
Thermography uses infrared technology to capture a picture of the body's image without the use of radiation or invasive technology. Data on the body's skin temperature is sent to a computer that converts the patterns to images which are read by a physician looking for abnormalities. As cancer grows, its need for nutrients increases and this activity causes increases in temperatures (neoangiogenesis). These temperature variations, caught by the infrared imaging, can be an early sign of cancer or pre-cancerous activity.
Finally, the Company is pleased to announce that Dr. Trip Chaudhury, M.D., Board Certified in Oncology, with practices in Beaumont and Houston, who completed a dissertation in Medical School on neoangiogenisis, has joined the Company's Advisory Board. "He is a perfect fit for our Advisory Board," Dr. Stucki said.
CONTACT: Dr. J.W. Stucki, CEO American HealthChoice, Inc. 817/837-8000 Paul Knopick E & E Communications 949/707-5365 firstname.lastname@example.org
|SOURCE American HealthChoice, Inc.|
Copyright©2008 PR Newswire.
All rights reserved